A network strategy to advance public health in Europe
Semenza, J.C., Apfel, F., Rose, T., Giesecke, J.
Preventing and controlling disease outbreaks in a complex emergency situation: discussion of the tsunami aftermath.
Eurosurveillance Editorial Team
Field investigation with real-time virus genetic characterisation support of a cluster of Ebola virus disease cases in Dubréka, Guinea, April to june 2015
Pini, A., Zomahoun, D., Duraffour, S., Derrough, T., Charles, M., Quick, J., Loman, N., Cowley, L., Leno, M., Ouedraogo, N., Thiam, O., Hernández-Romieu, A., Iko, A., Keita, H., Konate, D., Soumah, A.A., Bouchouar, E., Ileka-Priouzeau, S., Keita, S., Diallo, B., Cisse, F., Jansa, J., Carroll, M., Günther, S., Severi, E., Formenty, P.
Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): Results from the burden of communicable diseases in Europe study, European Union and European economic countries, 2009 to 2013
Cassini, A., Colzani, E., Pini, A., Mangen, M.-J.J., Plass, D., McDonald, S.A., Maringhini, G., van Lier, A., Haagsma, J.A., Havelaar, A.H., Kramarz, P., Kretzschmar, M.E.
Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, july 2017 to March 2018
Gossner, C.M., Haussig, J.M., de Bellegarde de Saint Lary, C., Kaasik Aaslav, K., Schlagenhauf, P., Sudre, B.
Management and control of communicable diseases in schools and other child care settings: Systematic review on the incubation period and period of infectiousness
Czumbel, I., Quinten, C., Lopalco, P., Semenza, J.C.
Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK
This document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 vaccines in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK). The aim is to support but not define EU policy on COVID-19 vaccination.
European Medicines Agency: Treatments and vaccines for COVID-19
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also making use of real-world data to monitor the safety and effectiveness of medicines used in patients with COVID-19.